Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Luther A. Bartelt; Alena J. Markmann; Bridget Nelson; Jessica Keys; Heather Root; Heather Henderson; JoAnn Kuruc; Caroline Baker; D. Ryan Bhowmik; Yixuan J. Hou; Lakshmanane Premkumar; Caleb Cornaby; John L. Schmitz; Susan R. Weiss; Yara Park; Ralph S. Baric; Aravinda M. de Silva; Anne M. Lachiewicz; Sonia Napravnik; David van Duin; David M. Margolis

doi:10.1128/mbio.01751-22

Abstract

This is the authors' abstract. We don't add key points for this paper.

In this study, in a high-risk population of patients admitted for COVID-19, we found an earlier time to hospital discharge among participants receiving CCP with nAb titers of >1:640 compared with participants receiving CCP with a lower nAb titer and no CCP-related AEs. The significance of our research is in identifying a dose response of CCP and clinical outcomes based on nAb titer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bartelt et al. (2022) studied this question.

synapsesocial.com/papers/6ab1fe3d64a770a58bd7706e https://doi.org/10.1128/mbio.01751-22

View Full Paper

Ask AI

Bookmark

Share

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Abstract

Discussion

Cite This Study

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading